No preview available from this publisher — open the full story below.
AbbVie is set to acquire immunology drugmaker Apogee for a substantial $10.9 billion, as reported by WSJ. This major acquisition marks a significant strategic move within the pharmaceutical sector, expanding AbbVie's portfolio and reinforcing its position in specialized…
Market Samachar is a news aggregator. This article was originally published by The Wall Street Journal. Tap the button above to read the full story on their site.